Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study

Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study

BackgroundEtanercept biosimilar recombinant human TNF-α receptor II: IgG Fc fusion protein (rhTNFR-Fc) has showed its efficacy and safety in Chinese patients with rheumatoid arthritis. However, data on rhTNFR-Fc's application in juvenile idiopathic arthritis (JIA) is limited.MethodsA prospectiv...

Full description

Bibliographic Details
Main Authors: Xuefeng Xu, Xiaohui Liu, Wenjie Zheng, Jihong Xiao, Xiaozhong Li, Ling Wu, Lixia Zou, Qian Ouyang, Yaoyao Shangguan, Kezhao Lin, Xiaomei Dai, Yuanling Chen, Yiping Xu, Jianqiang Wu, Meiping Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pediatrics
Subjects:
juvenile idiopathic arthritis
etanercept biosimilar
disease activity
efficacy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.992932/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.992932/full

Similar Items